China · Delayed Price · Currency is CNY Kexing Biopharm Statistics
Total Valuation
Kexing Biopharm has a market cap or net worth of CNY 6.66 billion. The enterprise value is 7.45 billion.
| Market Cap | 6.66B |
| Enterprise Value | 7.45B |
Important Dates
The next estimated earnings date is Saturday, March 28, 2026.
| Earnings Date | Mar 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Kexing Biopharm has 198.11 million shares outstanding. The number of shares has increased by 6.36% in one year.
| Current Share Class | 198.11M |
| Shares Outstanding | 198.11M |
| Shares Change (YoY) | +6.36% |
| Shares Change (QoQ) | +0.72% |
| Owned by Insiders (%) | 51.38% |
| Owned by Institutions (%) | 9.76% |
| Float | 96.32M |
Valuation Ratios
The trailing PE ratio is 54.28 and the forward PE ratio is 53.82.
| PE Ratio | 54.28 |
| Forward PE | 53.82 |
| PS Ratio | 4.40 |
| PB Ratio | 3.88 |
| P/TBV Ratio | 4.51 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 144.43 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 36.41, with an EV/FCF ratio of -238.50.
| EV / Earnings | 59.35 |
| EV / Sales | 4.91 |
| EV / EBITDA | 36.41 |
| EV / EBIT | 77.73 |
| EV / FCF | -238.50 |
Financial Position
The company has a current ratio of 1.50, with a Debt / Equity ratio of 0.81.
| Current Ratio | 1.50 |
| Quick Ratio | 1.36 |
| Debt / Equity | 0.81 |
| Debt / EBITDA | 6.83 |
| Debt / FCF | -44.75 |
| Interest Coverage | 2.21 |
Financial Efficiency
Return on equity (ROE) is 7.34% and return on invested capital (ROIC) is 3.89%.
| Return on Equity (ROE) | 7.34% |
| Return on Assets (ROA) | 1.87% |
| Return on Invested Capital (ROIC) | 3.89% |
| Return on Capital Employed (ROCE) | 4.03% |
| Revenue Per Employee | 1.60M |
| Profits Per Employee | 132,593 |
| Employee Count | 947 |
| Asset Turnover | 0.47 |
| Inventory Turnover | 4.13 |
Taxes
| Income Tax | -50,392 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +82.13% in the last 52 weeks. The beta is 0.79, so Kexing Biopharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.79 |
| 52-Week Price Change | +82.13% |
| 50-Day Moving Average | 33.54 |
| 200-Day Moving Average | 39.84 |
| Relative Strength Index (RSI) | 48.15 |
| Average Volume (20 Days) | 2,894,128 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Kexing Biopharm had revenue of CNY 1.52 billion and earned 125.57 million in profits. Earnings per share was 0.62.
| Revenue | 1.52B |
| Gross Profit | 966.66M |
| Operating Income | 95.86M |
| Pretax Income | 122.35M |
| Net Income | 125.57M |
| EBITDA | 191.70M |
| EBIT | 95.86M |
| Earnings Per Share (EPS) | 0.62 |
Balance Sheet
The company has 612.79 million in cash and 1.40 billion in debt, with a net cash position of -785.28 million or -3.96 per share.
| Cash & Cash Equivalents | 612.79M |
| Total Debt | 1.40B |
| Net Cash | -785.28M |
| Net Cash Per Share | -3.96 |
| Equity (Book Value) | 1.72B |
| Book Value Per Share | 8.65 |
| Working Capital | 517.43M |
Cash Flow
In the last 12 months, operating cash flow was 46.14 million and capital expenditures -77.39 million, giving a free cash flow of -31.24 million.
| Operating Cash Flow | 46.14M |
| Capital Expenditures | -77.39M |
| Free Cash Flow | -31.24M |
| FCF Per Share | -0.16 |
Margins
Gross margin is 63.75%, with operating and profit margins of 6.32% and 8.28%.
| Gross Margin | 63.75% |
| Operating Margin | 6.32% |
| Pretax Margin | 8.07% |
| Profit Margin | 8.28% |
| EBITDA Margin | 12.64% |
| EBIT Margin | 6.32% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.08, which amounts to a dividend yield of 0.24%.
| Dividend Per Share | 0.08 |
| Dividend Yield | 0.24% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 45.28% |
| Buyback Yield | -6.36% |
| Shareholder Yield | -6.13% |
| Earnings Yield | 1.88% |
| FCF Yield | -0.47% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Kexing Biopharm has an Altman Z-Score of 3.02 and a Piotroski F-Score of 5.
| Altman Z-Score | 3.02 |
| Piotroski F-Score | 5 |